Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Stigma and pain in adolescents hospitalized for sickle cell vasoocclusive pain episodes
source: The Clinical Journal of Pain
year: 2018
authors: Martin SR, Cohen LL, Mougianis I, Griffin A, Sil S, Dampier C
summary/abstract:OBJECTIVES:
Sickle cell disease (SCD) pain and hospitalizations increase during adolescence and adolescents with SCD may be at-risk for experiencing health-related stigma, which may result in poor health outcomes. This study examined relations among health-related stigma, pain interference, social support, quality of life (QOL), and hospital outcomes (ie, loneliness, pain reduction, and length of stay [LOS]) in adolescents hospitalized with SCD pain.
MATERIALS AND METHODS:
Twelve- to 18-year-old adolescents (N=92) hospitalized with SCD pain completed measures of stigma, pain interference, social support, QOL, and state loneliness. Reduction of pain intensity during hospitalization and LOS were collected from medical chart review.
RESULTS:
Higher stigma was associated with higher pain interference, lower QOL, more loneliness, and less pain reduction in the hospital. Pain interference was positively associated with LOS.
DISCUSSION:
These preliminary findings highlight the importance of assessing and addressing SCD-related stigma and pain interference in adolescents hospitalized for SCD pain as these factors may influence treatment outcomes.
organization: Georgia State University, Georgia; Children's Healthcare of Atlanta, Georgia; Stanford Medicine, United States; Emory University, Georgia
DOI: 10.1097/AJP.0000000000000553
read more
+myBinderRelated Content
-
The Unveiling of Sickle Cell Anemia – A Life’s StoryThe doctors and nurses that I trusted so...
-
Sickle Cell Anemia Treatment & ManagementThe National Institutes of Health advise...
-
Living With Sickle Cell: ‘I Don’t Know What It Means to Be Without Pain’Once a month, she undergoes a grueling p...
-
Managing Pain From Sickle Cell DiseaseWhen you have sickle cell disease (SCD),...
-
Crizanlizumab designated FDA breakthrough therapy for potential in vaso-occlusive crisis preventionCrizanlizumab (SEG101), Novartis‘ inve...
-
Latoyia Webb – Sickle Cell Disease Survivorhttps://www.youtube.com/watch?v=BPxbgqtV...
-
New treatment plan leads to better pain control for acute sickle cell crisisThere’s new hope for the 70,000 to 80,...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.